ABVC BioPharma, Inc. (ABVC)

ABVC BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.14	0.68	0.25	0.06	0.09	5.83
Short-Term Investments	0.06	0.06	0.06	0.08	0.08	0.11
Cash & Short-Term Investments	0.2	0.75	0.31	0.14	0.16	5.94
Cash Growth	-6.79%	138.20%	124.51%	-13.41%	-97.29%	38.93%
Accounts Receivable	-	-	-	0.01	0.86	0.43
Other Receivables	0.2	0.76	1.16	0.75	0.51	-
Total Trade Receivables	0.2	0.76	1.16	0.76	1.37	0.43
Inventory	-	-	-	-	-	0.03
Other Current Assets	0.25	0.99	0.71	0.76	1.46	1.27
Total Current Assets	0.65	2.5	2.18	1.66	2.99	7.65
Net Property, Plant & Equipment	14.65	14.75	1.15	1.38	1.74	2
Long-Term Investments	1.85	1.88	2.26	2.53	0.84	0.93
Other Long-Term Assets	2.59	1.93	1.95	2.22	4.02	3.11
Total Assets	19.73	21.06	7.54	7.78	9.58	13.7

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	4.15	4.16	3.51	3.55	2.91	1.3
Short-Term Debt	0.09	0.76	0.84	0.9	1.89	1.64
Current Portion of Long-Term Debt	0.8	0.8	0.95	0.89	-	-
Current Portion of Leases	0.33	0.32	0.4	0.4	0.37	0.35
Unearned Revenue	0.01	0.01	0.08	0.08	0.01	0.01
Other Current Liabilities	0.01	0.12	0.77	0.29	0.36	0.39
Total Current Liabilities	5.39	6.16	6.56	6.1	5.54	3.69
Long-Term Leases	1.51	1.6	0.24	0.41	0.79	1.12
Other Long-Term Liabilities	-	-	0.02	0.02	0.01	0.01
Total Long-Term Liabilities	1.51	1.6	0.26	0.43	0.8	1.14
Total Liabilities	6.9	7.76	6.82	6.53	6.34	4.83

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.03	0.03	0.01	0.01	0	0.03
Treasury Stock	-8.91	-8.91	-8.91	-8.9	-9.1	-9.1
Additional Paid-in Capital	97.58	96.37	78.63	73.98	66.58	55.86
Accumulated Other Comprehensive Income	0.5	0.49	0.45	0.52	0.52	0.54
Retained Earnings	-78.42	-76.86	-68.95	-64.05	-54.9	-38.48
Total Common Shareholders' Equity	10.77	11.11	1.23	1.55	3.1	8.84
Minority Interest	2.06	2.19	-0.5	-0.3	0.14	0.03
Shareholders' Equity	12.83	13.3	0.72	1.25	3.24	8.87
Total Liabilities & Equity	19.73	21.06	7.54	7.78	9.58	13.7

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	2.73	3.47	2.43	2.6	3.05	3.11
Net Cash (Debt)	-2.53	-2.73	-2.12	-2.46	-2.89	2.82
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.11	-0.14	-0.18	-0.57	-0.91	0.89
Book Value	10.77	11.11	1.23	1.55	3.1	8.84
Book Value Per Share	0.47	0.55	0.11	0.36	0.98	2.79
Tangible Book Value	10.77	11.11	1.23	1.55	3.1	8.84
Tangible Book Value Per Share	0.47	0.55	0.11	0.36	0.98	2.79

SEC Filings: 10-K · 10-Q

Data Source: Fiscal.ai Last updated: May 18, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 6, 2026

Data Sources Report a data error